OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
PSYCH INVESTOR SUMMIT: RESEARCH & DEVELOPMENT
Join us on 7 July, 2021 for another global psychedelics industry event. Through our concise half-day programme, we will be showcasing the latest research and development in this exciting sector, alongside expanding businesses looking for capital – delivering the industry’s most promising opportunities directly to investors & funds.
Every PSYCH Investor Summit is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.
Speakers:
Rick Doblin (Founder and Executive Director, MAPS)
Christian Angermayer (Founder, atai Life Sciences)
Dr. Ben Sessa (Chief Medical Officer, Awakn Life Sciences)
Plus many more TBA
For Sponsorship & Media enquires contact our team.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS
PSYCH | Investor Summit: Europe & Asia – What Can Europe & Asia Learn From North America
PSYCH | Investor Summit: Europe & Asia – The Future of Psychedelic Medicine in Europe
PSYCH | Investor Summit: Europe & Asia – Psychedelic Patents & I.P.
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
Rising Tides: North American Drug Regulations And The Impact On Big Psychedelic Business
With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted loosening of drug restrictions and the impact on psychedelic business? This two-part series examines the commercial implications of regulatory frameworks and proposed changes in North America. Part 1: Paths and Parallels When looking forContinue reading
Dr. Carl Hart on the Impediment of Prolonged Research
Lengthy clinical trials and the siphoning of well-studied, ‘textbook’ psychedelics through a cumbersome medical approval regime are unnecessary in 2021, says Dr. Carl Hart. PSYCH caught up with the American psychologist and neuroscientist last week, following the release of his new book, Drug Use for Grown-Ups. Hart is a prolific, yet provocative figure in theContinue reading
For Better or For Worse: Enter the Psychedelics Celebrity
This week, MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced a partnership with self-help guru Deepak Chopra’s The Chopra Foundation, the first high-profile, celebrity-backed deal of its kind for a publicly traded psychedelics company. Few fine details on the partnership have been released, though the company said in an 18 May press release that itContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
